Evidence map›Paper›PMID 38410486›Full record

ArticleResearch square2024

Targeting

Haineng Xu, Erin George, David Gallo, Sergey Medvedev, Xiaolei Wang, Rosie Kryczka, Marc L Hyer, Jimmy Fourtounis, Rino Stocco, Elia Aguado-Fraile and 8 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in Research square, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors at 3 institutions in 1 country.

Haineng XuPenn Ovarian Cancer Research Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.ORCID 0000-0001-7195-4897
Erin GeorgePenn Ovarian Cancer Research Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
David GalloRepare Therapeutics, Inc., 7171 Frederick-Banting, Ville St-Laurent, QC, Canada.
Sergey MedvedevPenn Ovarian Cancer Research Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
Xiaolei WangPenn Ovarian Cancer Research Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
Rosie KryczkaRepare Therapeutics, Inc., 7171 Frederick-Banting, Ville St-Laurent, QC, Canada.
Marc L HyerRepare Therapeutics, Cambridge, MA, USA.
Jimmy FourtounisRepare Therapeutics, Inc., 7171 Frederick-Banting, Ville St-Laurent, QC, Canada.
Rino StoccoRepare Therapeutics, Inc., 7171 Frederick-Banting, Ville St-Laurent, QC, Canada.
Elia Aguado-FraileRepare Therapeutics, Cambridge, MA, USA.
Adam PetroneRepare Therapeutics, Cambridge, MA, USA.
Shou Yun YinRepare Therapeutics, Inc., 7171 Frederick-Banting, Ville St-Laurent, QC, Canada.
Ariya ShiwramRepare Therapeutics, Inc., 7171 Frederick-Banting, Ville St-Laurent, QC, Canada.
Matthew AndersonPenn Ovarian Cancer Research Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
Hyoung KimPenn Ovarian Cancer Research Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.ORCID https://orcid.org/0000-0002-9975-8545
Fang LiuPenn Ovarian Cancer Research Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
C Gary MarshallRepare Therapeutics, Cambridge, MA, USA.
Fiona SimpkinsPenn Ovarian Cancer Research Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.ORCID 0000-0002-0840-2368
Hospital of the University of Pennsylvania · USIo Therapeutics (United States) · USCancer Research Center · US

Funding

SPORE in Ovarian CancerP50CA228991 · NCI · JOHNS HOPKINS UNIVERSITY · PI Amanda Nickles Fader · 2018 to 2026
$20.5M
University of Pennsylvania Patient-derived Xenograft Development and Trials CenterU54CA283759 · NCI · UNIVERSITY OF PENNSYLVANIA · PI Nicolas Skuli · 2023 to 2026
$5.1M
A novel more effective genotoxic therapy for ovarian cancerR37CA215436 · NCI · UNIVERSITY OF PENNSYLVANIA · PI SIMPKINS, FIONA · 2018 to 2024
$2.6M
NCI NIH HHS P50 CA228991NCI NIH HHS R37 CA215436NCI NIH HHS U54 CA283759
6 · The paper itself

Abstract

Ovarian cancers (OVCAs) and endometrial cancers (EMCAs) with

Indexed as

ATRCCNE1 amplificationPKMYT1

Identifiers

PMID38410486
PMCPMC10896384
OpenAlexW4391880636

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.